479 related articles for article (PubMed ID: 30280836)
41. Immune response elicited by an intranasally delivered HBsAg low-dose adsorbed to poly-ε-caprolactone based nanoparticles.
Jesus S; Soares E; Costa J; Borchard G; Borges O
Int J Pharm; 2016 May; 504(1-2):59-69. PubMed ID: 26976502
[TBL] [Abstract][Full Text] [Related]
42. Delivery of an inactivated avian influenza virus vaccine adjuvanted with poly(D,L-lactic-co-glycolic acid) encapsulated CpG ODN induces protective immune responses in chickens.
Singh SM; Alkie TN; Nagy É; Kulkarni RR; Hodgins DC; Sharif S
Vaccine; 2016 Sep; 34(40):4807-13. PubMed ID: 27543454
[TBL] [Abstract][Full Text] [Related]
43. Immunization against HTLV-I with chitosan and tri-methylchitosan nanoparticles loaded with recombinant env23 and env13 antigens of envelope protein gp46.
Amirnasr M; Fallah Tafti T; Sankian M; Rezaei A; Tafaghodi M
Microb Pathog; 2016 Aug; 97():38-44. PubMed ID: 27235335
[TBL] [Abstract][Full Text] [Related]
44. Robust mucosal and systemic responses against HTLV-1 by delivery of multi-epitope vaccine in PLGA nanoparticles.
Kabiri M; Sankian M; Sadri K; Tafaghodi M
Eur J Pharm Biopharm; 2018 Dec; 133():321-330. PubMed ID: 30408519
[TBL] [Abstract][Full Text] [Related]
45. Chitosan-based particulate systems for the delivery of mucosal vaccines against infectious diseases.
Singh B; Maharjan S; Cho KH; Cui L; Park IK; Choi YJ; Cho CS
Int J Biol Macromol; 2018 Apr; 110():54-64. PubMed ID: 29054527
[TBL] [Abstract][Full Text] [Related]
46. The positive adjuvant effect of chitosan on antigen-specific cell-mediated immunity after chickens vaccination with live Newcastle disease vaccine.
Rauw F; Gardin Y; Palya V; Anbari S; Gonze M; Lemaire S; van den Berg T; Lambrecht B
Vet Immunol Immunopathol; 2010 Apr; 134(3-4):249-58. PubMed ID: 19939464
[TBL] [Abstract][Full Text] [Related]
47. Nasal vaccination with r4M2e.HSP70c antigen encapsulated into N-trimethyl chitosan (TMC) nanoparticulate systems: Preparation and immunogenicity in a mouse model.
Dabaghian M; Latifi AM; Tebianian M; NajmiNejad H; Ebrahimi SM
Vaccine; 2018 May; 36(20):2886-2895. PubMed ID: 29627234
[TBL] [Abstract][Full Text] [Related]
48. Delivery systems: a vaccine strategy for overcoming mucosal tolerance?
Mann JF; Acevedo R; Campo JD; Pérez O; Ferro VA
Expert Rev Vaccines; 2009 Jan; 8(1):103-12. PubMed ID: 19093777
[TBL] [Abstract][Full Text] [Related]
49. Delivery strategies to enhance oral vaccination against enteric infections.
Davitt CJ; Lavelle EC
Adv Drug Deliv Rev; 2015 Aug; 91():52-69. PubMed ID: 25817337
[TBL] [Abstract][Full Text] [Related]
50. Intranasal delivery of nanoparticle-based vaccines.
Marasini N; Skwarczynski M; Toth I
Ther Deliv; 2017 Jan; 8(3):151-167. PubMed ID: 28145824
[TBL] [Abstract][Full Text] [Related]
51. Novel application of trimethyl chitosan as an adjuvant in vaccine delivery.
Malik A; Gupta M; Gupta V; Gogoi H; Bhatnagar R
Int J Nanomedicine; 2018; 13():7959-7970. PubMed ID: 30538470
[TBL] [Abstract][Full Text] [Related]
52. Nasal nanovaccines.
Bernocchi B; Carpentier R; Betbeder D
Int J Pharm; 2017 Sep; 530(1-2):128-138. PubMed ID: 28698066
[TBL] [Abstract][Full Text] [Related]
53. Intranasal formulations: promising strategy to deliver vaccines.
Riese P; Sakthivel P; Trittel S; Guzmán CA
Expert Opin Drug Deliv; 2014 Oct; 11(10):1619-34. PubMed ID: 24962722
[TBL] [Abstract][Full Text] [Related]
54. Subunit-based mucosal vaccine delivery systems for pulmonary delivery - Are they feasible?
Marasini N; Kaminskas LM
Drug Dev Ind Pharm; 2019 Jun; 45(6):882-894. PubMed ID: 30767591
[TBL] [Abstract][Full Text] [Related]
55. Immunostimulatory effect of chitosan and quaternary chitosan: A review of potential vaccine adjuvants.
Li X; Xing R; Xu C; Liu S; Qin Y; Li K; Yu H; Li P
Carbohydr Polym; 2021 Jul; 264():118050. PubMed ID: 33910752
[TBL] [Abstract][Full Text] [Related]
56. Microparticles as vaccine adjuvants and delivery systems.
O'Hagan DT; Singh M
Expert Rev Vaccines; 2003 Apr; 2(2):269-83. PubMed ID: 12899577
[TBL] [Abstract][Full Text] [Related]
57. Modes of Action for Mucosal Vaccine Adjuvants.
Aoshi T
Viral Immunol; 2017; 30(6):463-470. PubMed ID: 28436755
[TBL] [Abstract][Full Text] [Related]
58. Simultaneous formulation of influenza vaccine and chitosan nanoparticles within CpG oligodesoxi nucleotides leads to dose-sparing and protects against lethal challenge in the mouse model.
Sadati SF; Jamali A; Abdoli A; Abedi-Valugerdi M; Gholami S; Alipour S; Soleymani S; Kheiri MT; Atyabi F
Pathog Dis; 2018 Nov; 76(8):. PubMed ID: 30184220
[TBL] [Abstract][Full Text] [Related]
59. Immune response by nasal delivery of hepatitis B surface antigen and codelivery of a CpG ODN in alginate coated chitosan nanoparticles.
Borges O; Cordeiro-da-Silva A; Tavares J; Santarém N; de Sousa A; Borchard G; Junginger HE
Eur J Pharm Biopharm; 2008 Jun; 69(2):405-16. PubMed ID: 18364251
[TBL] [Abstract][Full Text] [Related]
60. Inactivated infectious bronchitis virus vaccine encapsulated in chitosan nanoparticles induces mucosal immune responses and effective protection against challenge.
Lopes PD; Okino CH; Fernando FS; Pavani C; Casagrande VM; Lopez RFV; Montassier MFS; Montassier HJ
Vaccine; 2018 May; 36(19):2630-2636. PubMed ID: 29653848
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
